140 related articles for article (PubMed ID: 25112396)
1. Interim FDG PET scans in lymphoma: SUV measurement error may impair qPET methodology.
Laffon E; Marthan R
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2154. PubMed ID: 25112396
[No Abstract] [Full Text] [Related]
2. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
Hasenclever D; Kurch L; Mauz-Körholz C; Elsner A; Georgi T; Wallace H; Landman-Parker J; Moryl-Bujakowska A; Cepelová M; Karlén J; Álvarez Fernández-Teijeiro A; Attarbaschi A; Fosså A; Pears J; Hraskova A; Bergsträsser E; Beishuizen A; Uyttebroeck A; Schomerus E; Sabri O; Körholz D; Kluge R
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1301-8. PubMed ID: 24604592
[TBL] [Abstract][Full Text] [Related]
3. Sources of variability in FDG PET imaging and the qPET value: reply to Laffon and Marthan.
Hasenclever D; Kurch L; Kluge R
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2155-7. PubMed ID: 25112397
[No Abstract] [Full Text] [Related]
4. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDG PET in malignant lymphoma: significance of positive findings.
Castellucci P; Zinzani P; Pourdehnad M; Alinari L; Nanni C; Farsad M; Battista G; Tani M; Stefoni V; Canini R; Monetti N; Rubello D; Alavi A; Franchi R; Fanti S
Eur J Nucl Med Mol Imaging; 2005 Jul; 32(7):749-56. PubMed ID: 15785956
[TBL] [Abstract][Full Text] [Related]
6. The value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas.
Schrepfer T; Haerle SK; Strobel K; Schaefer N; Hälg RA; Huber GF
Laryngoscope; 2010 May; 120(5):937-44. PubMed ID: 20422687
[TBL] [Abstract][Full Text] [Related]
7. Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?
Adams HJ; Kwee TC
Nucl Med Commun; 2016 Dec; 37(12):1333-1334. PubMed ID: 27501435
[No Abstract] [Full Text] [Related]
8. Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients.
Rossi C; Kanoun S; Berriolo-Riedinger A; Dygai-Cochet I; Humbert O; Legouge C; Chrétien ML; Bastie JN; Brunotte F; Casasnovas RO
J Nucl Med; 2014 Apr; 55(4):569-73. PubMed ID: 24566003
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
[TBL] [Abstract][Full Text] [Related]
10. Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.
Okosun J; Warbey V; Shaw K; Montoto S; Fields P; Marcus R; Virchis A; McNamara C; Bower M; Cwynarski K
AIDS; 2012 Apr; 26(7):861-5. PubMed ID: 22333746
[TBL] [Abstract][Full Text] [Related]
11. An update on the role of interim restaging FDG-PET in patients with diffuse large B-cell lymphoma and Hodgkin lymphoma.
Moskowitz CH; Zelenetz A; Schoder H
J Natl Compr Canc Netw; 2010 Mar; 8(3):347-52. PubMed ID: 20202464
[TBL] [Abstract][Full Text] [Related]
12. End-of-treatment FDG-PET lacks usefulness in Hodgkin lymphoma.
Adams HJ; Kwee TC
Ann Hematol; 2016 Dec; 95(12):2083-2084. PubMed ID: 27590600
[No Abstract] [Full Text] [Related]
13. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
14. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: interobserver agreement and reproducibility across software platforms.
Tutino F; Puccini G; Linguanti F; Puccini B; Rigacci L; Kovalchuk S; Sciagrà R; Berti V
Nucl Med Commun; 2021 Mar; 42(3):284-291. PubMed ID: 33306623
[TBL] [Abstract][Full Text] [Related]
15. An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline.
Sarocchi M; Bauckneht M; Arboscello E; Capitanio S; Marini C; Morbelli S; Miglino M; Congiu AG; Ghigliotti G; Balbi M; Brunelli C; Sambuceti G; Ameri P; Spallarossa P
J Transl Med; 2018 Oct; 16(1):295. PubMed ID: 30359253
[TBL] [Abstract][Full Text] [Related]
16. Correlative imaging strategies implementing CT, MRI, and PET for staging of childhood Hodgkin disease.
Furth C; Denecke T; Steffen I; Ruf J; Voelker T; Misch D; Vondran F; Plotkin M; Stöver B; Henze G; Lemke AJ; Amthauer H
J Pediatr Hematol Oncol; 2006 Aug; 28(8):501-12. PubMed ID: 16912590
[TBL] [Abstract][Full Text] [Related]
17. Early relapse in a patient with Hodgkin's disease and negative interim FDG-PET.
Fanti S; Castellucci P; Stefoni V; Nanni C; Tani M; Rubello D; Ambrosini V; Zinzani PL; Franchi R
Ann Nucl Med; 2008 Jun; 22(5):429-32. PubMed ID: 18600422
[TBL] [Abstract][Full Text] [Related]
18. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of interim FDG-PET in Hodgkin lymphoma: systematic review and meta-analysis.
Adams HJ; Nievelstein RA; Kwee TC
Br J Haematol; 2015 Aug; 170(3):356-66. PubMed ID: 25868485
[TBL] [Abstract][Full Text] [Related]
20. Interim response assessment for Hodgkin lymphoma: size matters.
Elstrom RL
Leuk Lymphoma; 2012 Nov; 53(11):2095-6. PubMed ID: 22680772
[No Abstract] [Full Text] [Related]
[Next] [New Search]
